DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+9.69%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.51B
AUM Growth
+$5.51B
(+9.2%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
3.07%
Top 10 Holdings %
Top 10 Hldgs %
54.24%
Holding
168
New
43
Increased
28
Reduced
13
Closed
42
Top Buys
| 1 |
United Therapeutics
UTHR
|
$76.3M |
| 2 |
Merck
MRK
|
$67.9M |
| 3 |
Vera Therapeutics
VERA
|
$54.1M |
| 4 |
Legend Biotech
LEGN
|
$43.3M |
| 5 |
Centene
CNC
|
$27.9M |
Top Sells
| 1 |
Dynavax Technologies
DVAX
|
$67.3M |
| 2 |
Alignment Healthcare
ALHC
|
$59.1M |
| 3 |
Neurocrine Biosciences
NBIX
|
$40.4M |
| 4 |
CMRX
Chimerix, Inc.
CMRX
|
$32.1M |
| 5 |
InMode
INMD
|
$28M |
Sector Composition
| 1 | Healthcare | 89.05% |
| 2 | Real Estate | 0.41% |
| 3 | Financials | 0% |
| 4 | Industrials | 0% |
| 5 | Communication Services | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Enhabit
EHAB
$398M
| $46.1M | 0.84% |
4,779,864
-217,882
| -4% | -$2.1M |
|
27
Certara
CERT
$1.72B
| $45.9M | 0.83% |
3,926,099
+1,903,483
| +94% | +$22.3M |
|
28
Envista
NVST
$3.4B
| $43.3M | 0.79% |
2,215,845
+190,902
| +9% | +$3.73M |
|
29
BioCryst Pharmaceuticals
BCRX
$1.7B
| $42M | 0.76% |
4,692,000
-497,665
| -10% | -$4.46M |
|
30
CONMED
CNMD
$1.64B
| $36.5M | 0.66% |
700,271
+89,271
| +15% | +$4.65M |
|
31
Pharvaris
PHVS
$1.46B
| $35.5M | 0.64% |
2,017,464
| – | – |
|
32
Cullinan Oncology
CGEM
$455M
| $29M | 0.53% |
3,855,552
-5,287
| -0.1% | -$39.8K |
|
33
Praxis Precision Medicines
PRAX
$965M
| $28.9M | 0.52% |
686,931
+67,000
| +11% | +$2.82M |
|
34
Phreesia
PHR
$1.87B
| $28.9M | 0.52% |
1,014,577
+4,733
| +0.5% | +$135K |
|
35
Kymera Therapeutics
KYMR
$3B
| $28.5M | 0.52% |
653,000
+60,000
| +10% | +$2.62M |
|
36
Moderna
MRNA
$9.4B
| $27.6M | 0.5% |
+1,000,000
| New | +$27.6M |
|
37
Edgewise Therapeutics
EWTX
$1.54B
| $27.1M | 0.49% |
2,067,320
-11,189
| -0.5% | -$147K |
|
38
Embecta
EMBC
$835M
| $26.6M | 0.48% |
2,749,712
+29,177
| +1% | +$283K |
|
39
Day One Biopharmaceuticals
DAWN
$769M
| $24.2M | 0.44% |
3,723,131
+762,391
| +26% | +$4.96M |
|
40
Ventas
VTR
$30.8B
| $22.4M | 0.41% |
+354,000
| New | +$22.4M |
|
41
Liquidia Corp
LQDA
$2.54B
| $20.1M | 0.37% |
1,616,778
| – | – |
|
42
Cogent Biosciences
COGT
$1.81B
| $19M | 0.34% |
2,640,215
+6,353
| +0.2% | +$45.6K |
|
|
MREO
43
Mereo BioPharma
MREO
$283M
| $18.2M | 0.33% |
6,710,429
| – | – |
|
44
Inspire Medical Systems
INSP
$2.6B
| $18.2M | 0.33% |
+140,000
| New | +$18.2M |
|
45
Savara
SVRA
$582M
| $18.2M | 0.33% |
7,964,000
| – | – |
|
|
BBNX
46
Beta Bionics, Inc. Common Stock
BBNX
$840M
| $17M | 0.31% |
1,168,415
+152,415
| +15% | +$2.22M |
|
47
Xenon Pharmaceuticals
XENE
$3.04B
| $17M | 0.31% |
+542,020
| New | +$17M |
|
48
Veracyte
VCYT
$2.38B
| $16.9M | 0.31% |
+625,000
| New | +$16.9M |
|
|
SION
49
Sionna Therapeutics, Inc. Common Stock
SION
$1.16B
| $16.8M | 0.31% |
970,590
+223,590
| +30% | +$3.88M |
|
50
NeoGenomics
NEO
$1.1B
| $15.7M | 0.29% |
+2,148,000
| New | +$15.7M |
|